We determined the in vitro activity of fenticonazole against 318 vaginitis isolates of Candida and bacterial species and selected 28 isolates for time-kill studies. At concentrations equal to 4 MIC, fenticonazole reached the 99.9% killing endpoint by 10 h for Staphylococcus aureus, Streptococcus agalactiae, and Escherichia coli and by 17 h for Candida albicans and Candida parapsilosis; and at concentrations equal to 8 MIC, by 19 and 20 h for Candida glabrata and Candida tropicalis, respectively. At concentrations equal to 2 MIC, fenticonazole required 20 h to reach the above endpoint against C. albicans in mixed culture with S. aureus, S. agalactiae, or E. coli versus 17 h against C. albicans in pure culture. Supra-MICs are achievable in topically treated patients’ vaginal surfaces.
- Antimicrobial susceptibility testing
- Targeted therapy
- Vaginal isolates